Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is a San Diego-based commercial mRNA medicines and vaccines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines. News about Arcturus often centers on clinical trial progress, regulatory interactions and collaboration updates linked to its LUNAR® lipid-mediated delivery and STARR® self-amplifying mRNA (sa-mRNA) platforms.
Investors following ARCT news can expect regular updates on the companys RNA therapeutic candidates for ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), including interim data from Phase 1 and Phase 2 studies, safety and tolerability findings, biomarker changes and plans for longer-duration or pivotal trials. Disclosures have highlighted programs such as ARCT-032, an inhaled mRNA therapy for CF, and ARCT-810, an mRNA therapeutic candidate for OTC deficiency.
Arcturus also issues frequent announcements related to its infectious disease vaccine portfolio. These include developments for KOSTAIVE®, described as the first approved self-amplifying mRNA COVID-19 vaccine, along with sa-mRNA influenza candidates like ARCT-2138 and pandemic influenza A H5N1 candidate ARCT-2304. News items may cover Phase 1 or Phase 3 data, immunogenicity and safety results, and regulatory submissions or approvals in collaboration with CSL Seqirus and partners such as Meiji Seika Pharma.
Additional ARCT headlines often involve financial results, cash runway commentary, cost management actions, investor conference participation and SEC filings that provide corporate updates. Stock Titans ARCT news page aggregates these company press releases, regulatory disclosures and related coverage so readers can track how Arcturus clinical, regulatory and partnership milestones may influence sentiment around ARCT stock over time.
Arcturus Therapeutics (Nasdaq: ARCT), a global leader in mRNA medicines, announced its participation in several upcoming investor and scientific conferences. These include the TIDES USA on May 16, 2024, H.C. Wainwright BioConnect on May 20, 2024, Piper Sandler Lung Investor Conference on May 23, 2024, and Goldman Sachs Healthcare Conference on June 12, 2024. These events will feature presentations and fireside chats, providing the company with opportunities to showcase its advancements in infectious disease vaccines and treatments for liver and respiratory rare diseases.
Arcturus Therapeutics announces a positive first-quarter financial update and pipeline progress. The commercial manufacture of Kostaive is on track for the delivery of 4 million doses in Q3. The European Marketing Authorization decision is expected in Q3. Multiple Phase 3 trials demonstrate the breadth of the STARR vaccine platform. Important Phase 1 data for ARCT-2138 is anticipated in Q3. JP Morgan will monetize the company's investment in ARCALIS JV in Japan. Financially, revenues decreased due to the CSL agreement, while operating expenses increased. The net loss was $26.8 million, but the cash position remains strong, with a cash runway of at least three years.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.